MercadoLibre Stock And 2 High Growth Names Investors May Want On Their Radar

Global yields have recently eased as major central banks adjust liquidity tools, which has helped support appetite for higher growth opportunities. That backdrop puts extra focus on companies where analysts already expect strong earnings growth and solid balance sheets. This article looks at three stocks from the Healthy high growth potential screener that match that profile and explains what sets each one apart so you can judge whether they deserve a place on your radar.

The stocks covered in this article are only a starting sample, and the full Healthy high growth potential screen surfaced another 1,523 companies with similarly compelling growth and financial profiles that are not included here. If you want to move beyond a short list and actively identify your own ideas, head straight to the Healthy high growth potential screener to filter, analyze, and focus on the opportunities that best match your conviction.

Amylyx Pharmaceuticals (AMLX)

Amylyx Pharmaceuticals is a clinical-stage biotech company focused on treatments for neurodegenerative and rare endocrine conditions, which fits the Healthy high growth potential screener through its late and mid stage pipeline rather than current revenue. Its key growth link is AMX0035 and AMX0114, clinical programs that could open earnings potential if trials in ALS and other neurodegenerative diseases are successful. The company currently has no meaningful commercial revenue and a market cap of about US$3.9b, which means investors are mainly paying for its pipeline and balance sheet strength.

Amylyx Pharmaceuticals is worth attention if you are looking for growth that depends on clear clinical and regulatory milestones rather than broad market trends. The company has a pivotal LUCIDITY trial for avexitide in post bariatric hypoglycemia that met primary and secondary endpoints, plus AMX0035 and AMX0114 in neurodegeneration, so there are several potential shots at future earnings. At the same time, Amylyx is still loss making and funding intensive, with dilution and trial risk that could hurt shareholders if data or approvals disappoint. Analysts see meaningful upside if programs succeed and have already raised targets after the recent avexitide readout, yet the current price still reflects uncertainty. If you want exposure to high growth potential in rare disease with real binary risk, this is a story to follow closely.

Amylyx Pharmaceuticals hinges on binary trial outcomes and future earnings potential, not current sales. The real question is whether the growth story outweighs the clinical risk cycle revealed in the analyst forecasts for Amylyx Pharmaceuticals

Build your own high growth shortlist

Amylyx Pharmaceuticals and the other two stocks in this article all came from a single screener, but the real advantage comes when you shape your own filters. Use our flexible Screener to mix growth, balance sheet and valuation metrics around your own style, or lean on the curated starting points in our Investing Ideas.

MercadoLibre (MELI)

MercadoLibre runs a combined e commerce and fintech ecosystem across Latin America, with the Mercado Libre marketplace on one side and the Mercado Pago payments and credit platform on the other. It generates about US$35.2b in revenue from internet software and services, with activity spread across Brazil, Mexico, Argentina and other countries. The company has a market cap of about US$90.2b.

MercadoLibre may suit investors seeking exposure to earnings growth tied to a large, fast scaling fintech platform rather than solely an online marketplace. Mercado Pago connects payments, credit and investments across tens of millions of users. Analysts have published expectations for strong earnings and revenue growth, and this comes alongside pressure on margins, a high debt load and reliance on wholesale funding instead of customer deposits. The stock trades on a high P/E, and Simply Wall Street’s DCF suggests meaningful upside if growth and profitability track these expectations. That outcome depends on how the credit book, funding costs and cash flow develop from this point.

MercadoLibre’s earnings engine and high P/E often look out of sync. Before assuming the stock is stretched or cheap, review the analysis report for MercadoLibre which breaks down how growth, credit risk and cash flows really fit together.

Fabrinet (FN)

Fabrinet is a contract manufacturer that builds high speed optical transceivers, tunable lasers, transponders and related modules for data centers and telecom networks. This is its clearest link to the Healthy high growth potential theme as bandwidth demand and AI driven traffic increase the need for these components. It also manufactures lasers, sensors and custom optics for automotive, medical and industrial customers, so the theme related optical networking work sits within a broader manufacturing portfolio rather than the whole business. Fabrinet has a market cap of about US$17.3b, which reflects investor attention on its role in the global optical and data center supply chain.

Investors watching data center and AI build outs may want Fabrinet on their radar because it sits in the middle of that spending through high speed optical modules and data center interconnect work, with data center revenue recently contributing to record quarterly sales. Analysts are forecasting strong multi year earnings growth and improving returns on equity, yet the stock already trades at a premium P/E, so the market is pricing in a lot of that optimism. At the same time, heavy reliance on a few customers, high non cash earnings and ongoing capacity expansion mean any wobble in orders or margins could hit cash flow harder than headline earnings suggest. The real opportunity is deciding whether that growth profile and seasoned management team outweigh concentration and funding risks as the AI and optical cycle plays out.

Fabrinet’s premium P/E and AI exposure have investors excited, yet the real story lies in how earnings quality and customer dependence interact. The analyst forecasts for Fabrinet could reveal what the headline growth narrative quietly leaves out.

Seeking Fresh Alternatives Before They Fly?

Fresh breakouts and quiet momentum can be caught early, before the crowd reacts and pricing shifts. Scan these under the radar ideas while it matters and act now.

• Spot cash rich businesses before sentiment catches up by scanning the list of solid balance sheet and fundamentals (50 results) that keeps quality and resilience front and center.
• Explore the next leg of AI momentum by reviewing the 56 AI infrastructure stocks curated to spotlight companies supplying the backbone of accelerating compute demand.
• Review potential metal supply dynamics by considering the 28 best rare earth metal stocks focused on producers connected to long term technology trends.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com